Lazabemide

Last updated

Lazabemide
Lazabemide.svg
Clinical data
Routes of
administration 		Oral
ATC code
  • none
Legal status
Legal status
  • Development terminated
Identifiers
  • N-(2-aminoethyl)-5-chloro-pyridine-2-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
Formula C8H10ClN3O
Molar mass 199.64 g·mol−1

Lazabemide (proposed trade names Pakio, Tempium) is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) that was under development as an antiparkinsonian agent but was never marketed. [1]

References

  1. ↑ Henriot S, Kuhn C, Kettler R, Da Prada M (1994). "Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: Preclinical and clinical findings". In Tipton KF, Youdim MB, Barwell CJ, Callingham BA, Lyles GA (eds.). Amine Oxidases: Function and Dysfunction. Proceedings of the 5th International Amine Oxidase Workshop, Galway, Ireland, August 22–25, 1992. Journal of Neural Transmission. Supplementum. Vol. 41. pp. 321–325. doi:10.1007/978-3-7091-9324-2_42. ISBN   978-3-211-82521-1. PMID   7931245.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.